TW200833666A - Ansamycin formulations and methods of use thereof - Google Patents
Ansamycin formulations and methods of use thereofInfo
- Publication number
- TW200833666A TW200833666A TW096147191A TW96147191A TW200833666A TW 200833666 A TW200833666 A TW 200833666A TW 096147191 A TW096147191 A TW 096147191A TW 96147191 A TW96147191 A TW 96147191A TW 200833666 A TW200833666 A TW 200833666A
- Authority
- TW
- Taiwan
- Prior art keywords
- methods
- geldanamycin
- ansamycin
- formulations
- compositions
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 title 1
- 229960000885 rifabutin Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- AFFSZNHAULCEKY-WBYSVDBMSA-N Geldanamycin Analog Chemical compound N1C(=O)\C(C)=C/C=C/C(OC)C(OC(N)=O)\C(C)=C\C(C)C(O)C(OC)CC(C)CC2=C(O)C1=CC(=O)C2=O AFFSZNHAULCEKY-WBYSVDBMSA-N 0.000 abstract 1
- 101710113864 Heat shock protein 90 Proteins 0.000 abstract 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical class N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87434906P | 2006-12-12 | 2006-12-12 | |
| US91447707P | 2007-04-27 | 2007-04-27 | |
| US93991307P | 2007-05-24 | 2007-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200833666A true TW200833666A (en) | 2008-08-16 |
Family
ID=39410222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW096147191A TW200833666A (en) | 2006-12-12 | 2007-12-11 | Ansamycin formulations and methods of use thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7947670B2 (zh) |
| EP (1) | EP2126548A2 (zh) |
| JP (1) | JP2010512397A (zh) |
| KR (1) | KR20090098982A (zh) |
| AR (1) | AR064304A1 (zh) |
| AU (1) | AU2007332727A1 (zh) |
| BR (1) | BRPI0720277A2 (zh) |
| CA (1) | CA2672537A1 (zh) |
| CL (1) | CL2007003604A1 (zh) |
| MX (1) | MX2009006166A (zh) |
| NO (1) | NO20092274L (zh) |
| PE (1) | PE20081506A1 (zh) |
| TW (1) | TW200833666A (zh) |
| WO (1) | WO2008073424A2 (zh) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2678124C (en) * | 2003-11-17 | 2014-10-07 | Merck Eprova Ag | Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride |
| DK1716119T3 (da) | 2003-12-23 | 2013-06-10 | Infinity Discovery Inc | Analoger af benzoquinonholdige ansamyciner til behandling af cancer |
| EP1776365B1 (en) * | 2004-06-02 | 2011-08-03 | Sandoz Ag | Meropenem intermediate in crystalline form |
| EP1928826B1 (en) * | 2005-09-21 | 2013-04-24 | 4Sc Ag | Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors |
| WO2007053427A2 (en) * | 2005-10-31 | 2007-05-10 | Janssen Pharmaceutica N.V. | Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives |
| CA2656057C (en) * | 2006-06-16 | 2012-10-02 | H. Lundbeck A/S | Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
| RU2496780C2 (ru) * | 2006-10-27 | 2013-10-27 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Твердые формы |
| US8426396B2 (en) * | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
| EP2085397A1 (en) * | 2008-01-21 | 2009-08-05 | Esteve Quimica, S.A. | Crystalline form of abacavir |
| US7935817B2 (en) * | 2008-03-31 | 2011-05-03 | Apotex Pharmachem Inc. | Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof |
| AR071318A1 (es) * | 2008-04-15 | 2010-06-09 | Basilea Pharmaceutica Ag | Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso |
| ES2347619B1 (es) * | 2008-05-13 | 2011-09-15 | Consejo Superior De Investigaciones Cientificas (Csic) (50%) | Procedimiento para diseñar una terapia individual antitumoral basado en la deteccion de los niveles de proteina hsp90, el uso de inhibidores de la proteina hsp90 para la elaboracion de composiciones farmaceuticas, las composiciones asi obtenidas y sus aplicaciones. |
| US8097719B2 (en) * | 2008-07-15 | 2012-01-17 | Genesen Labs | Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem |
| WO2010045442A1 (en) | 2008-10-15 | 2010-04-22 | Infinity Discovery, Inc. | Ansamycin hydroquinone compositions |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| WO2011060328A1 (en) * | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| BR112012022910B1 (pt) | 2010-03-12 | 2021-08-10 | Omeros Corporation | Compostos inibidores de pde10, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos para tratar distúrbios neurológicos em um animal de sangue quente |
| WO2011133675A1 (en) * | 2010-04-21 | 2011-10-27 | Teva Pharmaceutical Industries Ltd. | Gabapentin enacarbil compositions |
| JP2013536859A (ja) * | 2010-09-01 | 2013-09-26 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ｈｔ２ｃアゴニストの非吸湿性塩 |
| EP2760859A1 (en) * | 2011-09-30 | 2014-08-06 | Sunshine Lake Pharma Co., Ltd | Crystalline forms of azilsartan and preparation and uses thereof |
| NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ716462A (en) * | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| AU2016250843A1 (en) | 2015-04-24 | 2017-10-12 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| JP6796083B2 (ja) | 2015-06-09 | 2020-12-02 | カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ | カプセル中の薬剤の噴霧乾燥ディスパーションからの迅速な溶解を達成するための製剤 |
| JP2018535969A (ja) | 2015-11-04 | 2018-12-06 | オメロス コーポレーション | Ｐｄｅ１０阻害剤の固体状態形態 |
| JP2017110205A (ja) * | 2015-12-11 | 2017-06-22 | 日本合成化学工業株式会社 | 結晶成長抑制剤 |
| MX2019009510A (es) * | 2017-02-10 | 2019-11-25 | Altum Pharmaceuticals Inc | Composiciones de complejos de galio (iii) para administracion oral. |
| CN110996918A (zh) * | 2017-04-24 | 2020-04-10 | 萨缪斯治疗股份有限公司 | Hsp90抑制剂口服配制品和相关方法 |
| CN111278808B (zh) * | 2017-09-07 | 2024-04-26 | 安兹克斯特殊目的有限责任公司 | 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式 |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| GB2581154B (en) | 2019-02-05 | 2022-09-28 | Colvistec Ag | Amorphous pharmaceutical compositions |
| CN111303230B (zh) * | 2020-03-09 | 2021-07-13 | 中国食品药品检定研究院 | 一种黄体酮共晶物及其制备方法和用途 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| GB2106111B (en) | 1981-09-17 | 1985-11-06 | Takeda Chemical Industries Ltd | Macbecin derivatives and their production |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| CA2127457A1 (en) | 1992-01-06 | 1993-07-22 | Walter P. Cullen | Process and uses for 4,5-dihydrogeldanamycin and its hydroquinone |
| US5387584A (en) * | 1993-04-07 | 1995-02-07 | Pfizer Inc. | Bicyclic ansamycins |
| CA2166320A1 (en) * | 1993-06-29 | 1995-01-12 | Randall James Gallaschun | Ansamycin derivatives as antioncogene and anticancer agents |
| US5932566A (en) * | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
| US5834472A (en) * | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| JP2001523221A (ja) | 1996-09-01 | 2001-11-20 | ファーモス コーポレイション | 親油性物質の促進された生物学的利用能のための固形共沈物 |
| PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| US6051607A (en) | 1998-07-02 | 2000-04-18 | Micro Therapeutics, Inc. | Vascular embolizing compositions comprising ethyl lactate and methods for their use |
| CA2338000C (en) | 1998-07-17 | 2009-12-15 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Water-soluble 4-thio-maleimido derivatives and methods for their production |
| US6188221B1 (en) | 1998-08-07 | 2001-02-13 | Van De Kop Franz | Method and apparatus for transmitting electromagnetic waves and analyzing returns to locate underground fluid deposits |
| US6682758B1 (en) * | 1998-12-22 | 2004-01-27 | The United States Of America As Represented By The Department Of Health And Human Services | Water-insoluble drug delivery system |
| WO2000037050A1 (en) | 1998-12-22 | 2000-06-29 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Water-insoluble drug delivery system |
| EP1027885B1 (en) * | 1999-02-09 | 2008-07-09 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
| DE60039379D1 (de) * | 1999-02-10 | 2008-08-21 | Pfizer Prod Inc | Pharmazeutische feste Dispersionen |
| ATE404178T1 (de) | 1999-02-10 | 2008-08-15 | Pfizer Prod Inc | Vorrichtung mit matrixgesteuerter wirkstofffreisetzung |
| DE60043163D1 (de) | 1999-07-09 | 2009-11-26 | Basf Se | Verfahren zur Herstellung von Pigmenten mit verbesserten coloristischen Eigenschaften |
| SE9904382D0 (sv) * | 1999-12-02 | 1999-12-02 | Siemens Elema Ab | High Frequency Oscillation Patient Ventilator System |
| US6964978B2 (en) * | 1999-12-08 | 2005-11-15 | Pharmacia Corporation | Solid-state form of celecoxib having enhanced bioavailability |
| AR028253A1 (es) * | 2000-03-16 | 2003-04-30 | Pfizer Prod Inc | Inhibidores de la glucogeno fosforilasa |
| US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| US20050203612A1 (en) * | 2000-12-22 | 2005-09-15 | Avantec Vascular Corporation | Devices delivering therapeutic agents and methods regarding the same |
| US20040148232A1 (en) * | 2001-01-22 | 2004-07-29 | Osamu Fushimi | Electronic catalog aggregation apparatus for realizing fast and efficient electronic catalog system |
| EP1399190B1 (en) * | 2001-06-22 | 2010-09-08 | Bend Research, Inc. | Pharmaceutical compositions comprising low-solubility and acid-sensitive drugs and neutralized acidic polymers |
| EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
| JP2003006555A (ja) | 2001-06-25 | 2003-01-10 | Nova:Kk | コンテンツ配信方法、シナリオデータ、記録媒体およびシナリオデータ生成方法 |
| JP4032216B2 (ja) | 2001-07-12 | 2008-01-16 | ソニー株式会社 | 光学多層構造体およびその製造方法、並びに光スイッチング素子および画像表示装置 |
| US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| US20090197852A9 (en) | 2001-08-06 | 2009-08-06 | Johnson Robert G Jr | Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor |
| EP1420747A4 (en) | 2001-08-06 | 2010-06-02 | Kosan Biosciences Inc | ANSAMYCIN BENZOQUINONE |
| KR20040054692A (ko) * | 2001-09-24 | 2004-06-25 | 콘포마 세러퓨틱스 코포레이션 | 17-알릴 아미노 겔다나마이신 (17-ａａｇ) 및 기타안사마이신의 제조 방법 |
| BR0307344A (pt) * | 2002-02-01 | 2004-12-14 | Pfizer Prod Inc | Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica |
| DE60327994D1 (de) * | 2002-02-08 | 2009-07-30 | Conforma Therapeutics Corp | Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften |
| US20060014730A1 (en) * | 2002-04-10 | 2006-01-19 | Conforma Therapeutics Corporation | Ansamycin formulations and methods for producing and using same |
| AU2003277299B2 (en) | 2002-04-10 | 2009-12-10 | Conforma Therapeutics Corporation | Drug formulations having long and medium chain triglycerides |
| US20060024357A1 (en) | 2004-05-12 | 2006-02-02 | Medivas, Llc | Wound healing polymer compositions and methods for use thereof |
| US20060019941A1 (en) | 2003-12-23 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Analogs of benzoquinone-containing ansamycins and methods of use thereof |
| DK1716119T3 (da) * | 2003-12-23 | 2013-06-10 | Infinity Discovery Inc | Analoger af benzoquinonholdige ansamyciner til behandling af cancer |
| CA2551254A1 (en) * | 2003-12-31 | 2005-07-21 | Pfizer Products Inc. | Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers |
| AU2005228886A1 (en) | 2004-03-26 | 2005-10-13 | Michigan State University | Geldanamycin and derivatives inhibit cancer invasion and identify novel targets |
| US20050256097A1 (en) * | 2004-05-11 | 2005-11-17 | Kosan Biosciences, Inc. | Pharmaceutical solution formulations containing 17-AAG |
| US7179708B2 (en) * | 2004-07-14 | 2007-02-20 | Chung Yuan Christian University | Process for fabricating non-volatile memory by tilt-angle ion implantation |
| WO2006034147A2 (en) | 2004-09-16 | 2006-03-30 | Abraxis Bioscience, Inc. | Compositions and methods for the preparation and administration of poorly water soluble drugs |
| US20060067953A1 (en) * | 2004-09-29 | 2006-03-30 | Conforma Therapeutics Corporation | Oral pharmaceutical formulations and methods for producing and using same |
| AU2005302000A1 (en) | 2004-11-02 | 2006-05-11 | Conforma Therapeutics Corporation | Methods and compositions for treating chronic lymphocytic leukemia |
| WO2006089207A2 (en) | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Inc. | Drugs with improved hydrophobicity for incorporation in medical devices |
| EP1853238A4 (en) | 2005-02-28 | 2008-07-23 | Kosan Biosciences Inc | PHARMACEUTICAL FORMULATIONS WITH 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN |
| EP1863769A4 (en) * | 2005-03-11 | 2009-03-18 | Univ Colorado | HSP90 INHIBITORS, METHOD FOR THE PRODUCTION THEREOF AND THEIR APPLICATIONS |
| EP1871361A2 (en) * | 2005-04-07 | 2008-01-02 | Conforma Therapeutics Corporation | Phospholipid-based pharmaceutical formulations and methods for producing and using same |
| AU2006242540A1 (en) * | 2005-04-29 | 2006-11-09 | Kosan Biosciences Incorporated | Method of treating multiple myeloma using 17-AAG of 17-AG of a prodrug of either |
| AU2006242446A1 (en) * | 2005-04-29 | 2006-11-09 | Kosan Biosciences Incorporated | Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor |
| WO2007002093A2 (en) * | 2005-06-21 | 2007-01-04 | Infinity Discovery, Inc. | Ansamycin formulations and methods of use thereof |
| EP1897871A4 (en) | 2005-06-29 | 2009-12-09 | Kyowa Hakko Kirin Co Ltd | ANSAMYCIN BENZENOID DERIVATIVE |
| US20070026072A1 (en) * | 2005-07-28 | 2007-02-01 | Stephen Olsen | Benzoquinones of enhanced bioavailability |
| WO2007059116A2 (en) | 2005-11-14 | 2007-05-24 | Abraxis Bioscience, Inc. | Geldanamycin derivatives and pharmaceutical compositions thereof |
| US20090042847A1 (en) * | 2005-11-23 | 2009-02-12 | Kosan Biosciences Incorporated | 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations |
| EP1954265A2 (en) | 2005-12-01 | 2008-08-13 | Conforma Therapeutics Corporation | Compositions containing ansamycin |
| US20070167422A1 (en) | 2006-01-18 | 2007-07-19 | Yu Kwok S | Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin |
-
2007
- 2007-12-10 PE PE2007001752A patent/PE20081506A1/es not_active Application Discontinuation
- 2007-12-11 BR BRPI0720277-6A patent/BRPI0720277A2/pt not_active IP Right Cessation
- 2007-12-11 TW TW096147191A patent/TW200833666A/zh unknown
- 2007-12-11 KR KR1020097014619A patent/KR20090098982A/ko not_active Withdrawn
- 2007-12-11 CL CL2007003604A patent/CL2007003604A1/es unknown
- 2007-12-11 MX MX2009006166A patent/MX2009006166A/es not_active Application Discontinuation
- 2007-12-11 JP JP2009541348A patent/JP2010512397A/ja active Pending
- 2007-12-11 WO PCT/US2007/025317 patent/WO2008073424A2/en not_active Ceased
- 2007-12-11 EP EP07867704A patent/EP2126548A2/en not_active Withdrawn
- 2007-12-11 CA CA002672537A patent/CA2672537A1/en not_active Abandoned
- 2007-12-11 AU AU2007332727A patent/AU2007332727A1/en not_active Abandoned
- 2007-12-11 US US12/001,239 patent/US7947670B2/en not_active Expired - Fee Related
- 2007-12-12 AR ARP070105568A patent/AR064304A1/es not_active Application Discontinuation
-
2008
- 2008-08-20 US US12/229,326 patent/US8357676B2/en not_active Expired - Fee Related
- 2008-08-20 US US12/229,277 patent/US8283343B2/en not_active Expired - Fee Related
-
2009
- 2009-06-12 NO NO20092274A patent/NO20092274L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20092274L (no) | 2009-08-25 |
| US20080221077A1 (en) | 2008-09-11 |
| AR064304A1 (es) | 2009-03-25 |
| MX2009006166A (es) | 2009-08-26 |
| US20090069281A1 (en) | 2009-03-12 |
| JP2010512397A (ja) | 2010-04-22 |
| KR20090098982A (ko) | 2009-09-18 |
| CL2007003604A1 (es) | 2009-01-23 |
| PE20081506A1 (es) | 2008-12-09 |
| CA2672537A1 (en) | 2008-06-19 |
| US8357676B2 (en) | 2013-01-22 |
| AU2007332727A1 (en) | 2008-06-19 |
| WO2008073424A3 (en) | 2008-07-31 |
| BRPI0720277A2 (pt) | 2014-01-28 |
| WO2008073424A2 (en) | 2008-06-19 |
| US7947670B2 (en) | 2011-05-24 |
| US8283343B2 (en) | 2012-10-09 |
| WO2008073424A9 (en) | 2008-10-02 |
| EP2126548A2 (en) | 2009-12-02 |
| US20090062528A1 (en) | 2009-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200833666A (en) | Ansamycin formulations and methods of use thereof | |
| AU2003280087A8 (en) | Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton | |
| WO2007096151A3 (en) | Inhibitors of p38-kinase for treatment of pulmonary hypertension | |
| TW200604179A (en) | Pyrazole derivatives, compositions containing such compounds and methods of use | |
| TW200722100A (en) | A therapeutic agent for a β related disorders | |
| IL164896A (en) | Pharmaceutical compositions comprising immunoconjugates for the treatment of tumors | |
| PT1696905E (pt) | 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson | |
| IL193252A0 (en) | N-hydroxyacrylamide compounds | |
| GB0222514D0 (en) | Organic compounds | |
| WO2005115470A3 (fr) | COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS | |
| TW200626553A (en) | Novel compounds | |
| MY133512A (en) | Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | |
| TW200745044A (en) | Pyrazole derivatives, compositions containing such compounds and methods of use | |
| WO2008004100A3 (en) | Therapeutic compounds | |
| ZA200700945B (en) | Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases | |
| MXPA05007253A (es) | Sales novedosas de derivados anticonvulsivantes. | |
| MY140986A (en) | S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same | |
| WO2008014232A3 (en) | Pharmaceutical formulations for the treatment of alzheimer's disease | |
| WO2007139948A3 (en) | Imidazoazepinone compounds | |
| MXPA03010919A (es) | Uso de acetil l-carnitina para preparacion de medicamento para terapia preventiva del dolor. | |
| TW200633701A (en) | Thioether derivatives, their manufacture and use as pharmaceutical agents | |
| UA87292C2 (ru) | Применение сирамезина для лечения злокачественных опухолей | |
| TW200626149A (en) | Tricycles, their manufacture and use as pharmaceutical agents | |
| WO2008034895A3 (en) | Ansamycin derivatives | |
| WO2007052167A3 (en) | Stable composition for a pharmaceutical formulation containing olanzapine |